LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.…
LB Pharmaceuticals Inc.: Q3 Earnings Snapshot
LB Pharmaceuticals (NASDAQ: LBRX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 62 employees.
The shares were at 38.85 USD on 20 November 2026, up 144.7% over 52 weeks. Its 52-week range is 15.19 USD to 50.16 USD: the price is 22.5% below the high and 155.8% above the low.
Its market capitalisation is 1.26B USD.
LB Pharmaceuticals reports return on equity of -8.4% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 398.60M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 11 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 58.00 USD is 49.3% above the current price. The next earnings report is expected on 25 March 2027.